Syncona Regulatory News (SYNC)

Syncona Limited - Total Voting Rights

PR Newswire

London, August 31

31 August 2017

Syncona Limited

Total Voting Rights

Pursuant to DTR 5.6.1 Syncona Limited (the “Company”) announces that as at 31 August 2017 the total number of ordinary shares in issue now stands at 659,952,090 and the total number of voting rights in the Company is 659,952,090 ordinary shares.

The Company does not hold any ordinary shares in treasury.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

[ENDS]

Enquiries

Northern Trust International Fund Administration Services (Guernsey) LimitedCompany SecretaryTel: 01481 745001

Copies of this announcement and other corporate information can be found on the company website at:www.synconaltd.com 

About Syncona:

Syncona is a leading FTSE250 healthcare company focused on investing in and building global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders. Our current investment portfolio consists of seven high quality companies in life science and a leading range of fund investments.

We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses. We are established leaders in gene therapy, cell therapy and advanced diagnostics, and focus on delivering dramatic efficacy for patients in areas of high unmet need.

Our market leading funds portfolio seeks to generate superior returns by investing in long only and alternative investment funds. This represents a productively deployed evergreen funding base which enables us to take a long term approach to investing in life sciences as we target the best new opportunities and support our existing portfolio companies to grow and succeed.

Syncona is aligned with two of the premium charitable funders in UK science, the Wellcome Trust, original founder of Syncona, and Cancer Research UK, both of which are significant shareholders in our business. We make a donation of 0.3% of Net Asset Value to a range of charities each year.